Poly Medicure reported a 12.3% increase in consolidated revenue to ₹1,995.3 crore for the financial year ended March 31, 2026, while net profit declined 5.3% to ₹320.7 crore. The company recorded an exceptional item of ₹6.80 lakh related to the impact of new Labour Codes. The Board of Directors recommended a dividend of ₹3.5 per share. Looking ahead, the company targets FY27 revenue of ₹2,300 crore.

Financial Performance

For the financial year 2025-26, consolidated revenue from operations rose to ₹1,995.3 crore, compared to ₹1,758.9 crore in the previous year. On a quarterly basis, revenue for the fourth quarter ended March 31, 2026, was ₹552.3 crore, up from ₹465.1 crore in the same quarter of the prior year. The company reported a consolidated net profit of ₹320.7 crore for the full year, a decrease from ₹338.6 crore in the previous year. For the fourth quarter, the net profit was ₹65.0 crore, a decline from ₹91.8 crore in the corresponding quarter of the previous year.

The following table summarizes the key financial metrics for the year and quarter ended March 31, 2026:

Operational Metrics and Margins

The consolidated operating EBITDA margin for FY26 stood at 24.4%, while the standalone operating EBITDA margin was 26.8%, near the upper end of the company's 25-27% guidance range. Gross profit margin expanded by 130 basis points in FY26 to 68.1%, led by an improving product mix and cost optimization initiatives. The company maintained adequate liquidity with cash and cash equivalents of ₹842.2 crore as of March 31, 2026, and incurred a capital expenditure of ₹296 crore during the year.

Segment and Geographic Performance

Infusion therapy remained the largest segment, contributing ₹1,012.4 crore to revenue, while the 'Others' segment, which includes critical care and cardiology, saw significant growth of 36.3% to ₹506.7 crore. Geographically, revenue from India grew 19.6% to ₹581.7 crore, Europe grew 7.1% to ₹597.0 crore, and the Rest of the World grew 11.4% to ₹683.2 crore.

Revenue Outlook

Poly Medicure expects its FY27 revenue to reach ₹2,300 crore, compared to ₹1,900 crore in FY26. The following table outlines the company's revenue guidance:

Dividend Declaration

The Board of Directors has recommended a dividend of ₹3.5 per equity share, which constitutes 70% of the face value of ₹5 each, for the financial year 2025-26. This dividend is subject to the approval of shareholders at the Annual General Meeting.

Corporate Developments

During the year, the Group completed the acquisition of 90% economic rights in the Pendracare Group and 100% economic rights in Medistream SA, Switzerland. The company also received approval from the National Company Law Tribunal (NCLT) for a resolution plan regarding Himalayan Mineral Water Private Limited, involving a payment of ₹33.16 crore. Additionally, the company acquired Medyneo, a Brazil-based medical device company, to commercialize operations in the region.

Poly Medicure has made available the audio recording of its earnings conference call held on Monday, May 25, 2026, to discuss the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The disclosure was made pursuant to Regulation 30 and 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Access to Recording

The audio file of the conference call, which commenced at 05:00 P.M. Indian time, is hosted on the company's official website. Stakeholders can access the recording directly via the provided link to review the management's commentary on the financial performance for Q4 and FY26.

Financial Context

The conference call followed the board meeting convened on the same day to consider and approve the audited financial results for the financial year ended March 31, 2026. The board had also deliberated on the recommendation of a final dividend, if any. The trading window for dealing in the company's securities was scheduled to remain closed until May 27, 2026.

Key Participants

During the original call, key executives presented the financial performance. The management team included Himanshu Baid as Managing Director, Naresh Vijayvergiya as Chief Financial Officer, and Rahul Gautam as President- Strategy & Corporate Development.